• What We Do
  • Who We Are
  • Resources
  • News
  • GIVESMART

Search Results

Calvarial Cleidocraniodysplasia-Like Defects With ENU-induced Nell-1 Deficiency

Calvarial Cleidocraniodysplasia-Like Defects With ENU-induced Nell-1 Deficiency

by Bandera Admin | May 21, 2020 | Resources

Nell-1, first identified by its overexpression in synostotic cranial sutures, is a novel osteoinductive growth and differentiation factor. To further define Nell-1’s role in craniofacial patterning, we characterized defects of the ENU-induced Nell-1-deficient...
Genetic Analysis in the Collaborative Cross Breeding Population

Genetic Analysis in the Collaborative Cross Breeding Population

by Bandera Admin | May 21, 2020 | Resources

Genetic reference populations in model organisms are critical resources for systems genetic analysis of disease related phenotypes. The breeding history of these inbred panels may influence detectable allelic and phenotypic diversity. The existing panel of common...
NELL-1, an Osteoinductive Factor, Is a Direct Transcriptional Target of Osterix

NELL-1, an Osteoinductive Factor, Is a Direct Transcriptional Target of Osterix

by Bandera Admin | May 21, 2020 | Resources

NELL-1 is a novel secreted protein associated with premature fusion of cranial sutures in craniosynostosis that has been found to promote osteoblast cell differentiation and mineralization. Our previous study showed that Runx2, the key transcription factor in...
Human NELL1 Protein Augments Constructive Tissue Remodeling With Biologic Scaffolds

Human NELL1 Protein Augments Constructive Tissue Remodeling With Biologic Scaffolds

by Bandera Admin | Apr 9, 2020 | Resources

Biologic scaffolds composed of extracellular matrix (ECM) derived from decellularized tissues effectively reprogram key stages of the mammalian response to injury, altering the wound microenvironment from one that promotes scar tissue formation to one that stimulates...
Next Entries »

Categories

  • News
  • Resources

Recent Posts

  • NellOne Therapeutics utilizes ORNL’s “COVID-19 Rapid Access Licensing Program”
  • NellOne Therapeutics partners with ORNL on COVID-19 drug delivery system
  • Anti-inflammatory molecules that treat cystic fibrosis may fight COVID-19
  • CEO Bill Malkes featured on Startup Knox Podcast
  • NellOne Therapeutics secures key patent to revolutionize large-scale production
  • What We Do
  • Who We Are
  • Resources
  • News
  • GIVESMART

contact us



(865) 300-7161



hello@nell-one.com



11020 Solway School Rd

Knoxville, TN 37931

© NELLONE 2020 ALL RIGHTS RESERVED     |     SITE DESIGN BY BANDERA